Expertise in
28
conditions

Jorg C. Henes

Otfried Müller Str. 10, 
Tuebingen, BW, DE 
Expertise in
28
conditions
Otfried Müller Str. 10, 
Tuebingen, BW, DE 

Overview

Jorg Henes practices practicing medicine in Tuebingen, Germany.

Henes is highly rated in 28 conditions, according to our data. Their clinical expertise encompasses Scleroderma, Systemic Sclerosis (SSc), Vasculitis, Bone Marrow Transplant, and Bone Graft.

They are actively involved in clinical research, co-authoring 244 peer reviewed articles and participating in 6 clinical trials.

Locations

Otfried Müller Str. 10, Tuebingen, BW 72076, Germany
Other Locations
Hoppe Seyler Str. 3, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Study Protocol for a Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's Disease (AOSD) Including an Open-label Long Term Extension
Enrollment Status: Terminated
Publish Date: August 07, 2020
Intervention Type: Drug
Study Phase: Phase 2
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis: a Prospective Non-Interventional Approach Across Europe (NISSC) for the Autoimmune Diseases Working Party of the EBMT
Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis: a Prospective Non-Interventional Approach Across Europe (NISSC) for the Autoimmune Diseases Working Party of the EBMT
Enrollment Status: Completed
Publish Date: May 01, 2018
Intervention Type: Procedure
View 4 Less Clinical Trials

244 Total Publications

Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.
Management of major organ involvement in Behçet syndrome: a systematic literature review informing the 2025 update of the EULAR recommendations.
Journal: EULAR rheumatology open
Published: August 01, 2026

Frequently Asked Questions about Jorg C. Henes

Is Jorg C. Henes a top-rated expert for Scleroderma?

MediFind is an objective health platform that identifies experts based on real-world data. Jorg C. Henes is classified as an Elite expert for Scleroderma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jorg C. Henes participate in research or clinical trials?

Yes. Jorg C. Henes has published 244 articles and abstracts on conditions like Scleroderma. You can view a list of Jorg C. Henes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Henes's expertise for a condition
ConditionClose
View All 21 Advanced Conditions
View All 61 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile